| Ameliorative effects of telmisartan in diabetic rats with indomethacin-induced gastric ulceration. | |
| | |
MedLine Citation:
|
PMID: 20399771 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The protective effects of telmisartan, the angiotensin II-receptor antagonist, were investigated in rats with type 2 diabetes mellitus exposed to acute gastric ulceration. Following successful induction of diabetes, telmisartan treatment (1 mg/kg/day, orally) was started and continued for 8 weeks, after which acute gastric ulceration was induced by indomethacin. Telmisartan significantly attenuated the hyperglycemia and hypoinsulinemia in diabetic rats. Also, telmisartan significantly reduced the elevations of total gastric acid output, pepsin activity, gastric ulcer index and gastric mucosal tumor necrosis factor-alpha, nitric oxide, malondialdehyde and caspase-3 activity, and restored the depleted antioxidant defenses (reduced glutathione level, and superoxide dismutase and catalase activities) caused by indomethacin administration in diabetic rats. Histopathological gastric tissue damage induced by indomethacin in diabetic rats was ameliorated by telmisartan treatment. Immunohistochemical analysis revealed that telmisartan markedly attenuated the reduction in insulin content of pancreatic islet beta-cells, and prevented the indomethacin-induced overexpression of inducible nitric oxide synthase and nuclear factor-kappaB in gastric mucosa of diabetic rats. It was concluded that telmisartan represents a potential therapeutic option to reduce the risk of gastric ulceration induced by nonsteroidal anti-inflammatory drugs in type 2 diabetic patients. |
| | |
Authors:
|
Amr A Fouad; Ali Ibrahim Al-Sultan; Mohamed T Yacoubi; Wafaey Gomaa |
Publication Detail:
|
Type: Journal Article Date: 2010-04-23 |
Journal Detail:
|
Title: European journal of pharmacology Volume: 637 ISSN: 1879-0712 ISO Abbreviation: Eur. J. Pharmacol. Publication Date: 2010 Jul |
Date Detail:
|
Created Date: 2010-05-31 Completed Date: 2010-09-07 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 1254354 Medline TA: Eur J Pharmacol Country: Netherlands |
Other Details:
|
Languages: eng Pagination: 162-70 Citation Subset: IM |
Copyright Information:
|
Copyright 2010 Elsevier B.V. All rights reserved. |
Affiliation:
|
Department of Biomedical Sciences, Pharmacology Division, College of Medicine, Al-Ahsa, King Faisal University, Saudi Arabia. amrfouad65@yahoo.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Angiotensin II Type 1 Receptor Blockers
/
pharmacology* Animals Antioxidants / metabolism Benzimidazoles / pharmacology* Benzoates / pharmacology* Blood Glucose / metabolism Caspase 3 / metabolism Diabetes Mellitus, Type 2 / complications*, drug therapy* Gastric Acid / secretion Gastric Mucosa / drug effects, metabolism, pathology Humans Immunohistochemistry Indomethacin* Insulin / metabolism Male Malondialdehyde / metabolism Nitric Oxide / metabolism Rats Rats, Sprague-Dawley Stomach Ulcer / chemically induced*, complications, drug therapy*, metabolism Tumor Necrosis Factor-alpha / metabolism |
| Chemical | |
Reg. No./Substance:
|
0/Angiotensin II Type 1 Receptor Blockers; 0/Antioxidants; 0/Benzimidazoles; 0/Benzoates; 0/Blood Glucose; 0/Tumor Necrosis Factor-alpha; 10102-43-9/Nitric Oxide; 11061-68-0/Insulin; 144701-48-4/telmisartan; 53-86-1/Indomethacin; 542-78-9/Malondialdehyde; EC 3.4.22.-/Caspase 3 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The glial cell modulator and phosphodiesterase inhibitor, AV411 (ibudilast), attenuates prime- and s...
Next Document: NF-kappaB signaling mediates vascular smooth muscle endothelin type B receptor expression in resista...